A possibility for health improvement in overweight and obese women at the stage of pregravid preparation

Radzinsky V.E., Solovyeva A.V., Kuleshov V.M., Katkova N.Yu., Mingaleva N.V., Korotkikh I.N., Oboskalova T.A., Vorontsova A.V.

1) Department of Obstetrics and Gynecology with a Perinatology Course, Medical Institute, Peoples’ Friendship University of Russia (RUDN University), Ministry of Education and Science of the Russian Federation, Moscow, Russia; 2) Novosibirsk State Medical University, Ministry of Health of the Russian Federation, Novosibirsk, Russia; 3) Volga Research Medical University, Ministry of Health of the Russian Federation, Nizhny Novgorod, Russia; 4) Kuban State Medical University, Ministry of Health of the Russian Federation, Krasnodar, Russia; 5) N.N. Burdenko Voronezh State Medical University, Ministry of Health of the Russian Federation, Voronezh, Russia; 6) Ural State Medical University, Ministry of Health of the Russian Federation, Yekaterinburg, Russia
About half of women planning pregnancy have too much adipose tissue, insulin resistance, hypothalamic-pituitary-ovarian axis disorders, and consequently anovulation and infertility. Objective: To assess the results of using the biologically active dietary supplement Dikirogen (myo-inositol and D-chiroinositol in a ratio of 5:1) in conjunction with combination therapy for anovulation in overweight and obese women. Materials and methods: During 2021–2022, a descriptive study assessing the results of lifestyle changes (in diet and exercises) and nutritional support (a combination of myo-inositol 1000 mg and D-chiroinositol 200 mg, folic acid 200 μg, and manganese 5 mg (Dikirogen) was conducted in the clinics of Moscow, Nizhny Novgorod, Novosibirsk, Krasnodar, Yekaterinburg, and Voronezh in 197 reproductive-aged women who had overweight or obesity and anovulation for 2–4 months. Results: The use of the biologically active dietary supplement Dikirogen in conjunction with combination therapy (diet + exercises) caused decreases in body weight by 2.5 kg, body mass index (BMI) by 0.5 kg/m2, and waist circumference by 1.75 cm. The normal menstrual cycle was 1.41 times more often observed at Visit 2. There were reductions in LH levels from 8.45 (3.91) to 6.4 (4.9; 8.8) mU/ml and in the LH/FSH ratio from 1.4 (0.9; 2.0) to 1.2 (0.8; 1.6) (p<0.0001). There were also significant decreases in fasting glucose levels from 5.0 (4.5; 5.5) to 4.8 (4.2; 5.0) mmol/l (p<0.0001) and on the number of women with fasting glucose levels above 5.1 mmol/ml by 3.07 times. During 80–90 follow-up days, pregnancy occurred in 30 (15.2%) patients; at Visit 2, the ovulation test was positive in 96 (48.73%) women. Conclusion: The results of the study can recommend Dikirogen containing myo-inositol and D-chiroinositol in a ratio of 5:1, folic acid, and manganese in conjunction with combination therapy (diet, exercises) to obese and overweight women with complaints of anovulation and failure to achieve pregnancy, Authors' contributions: Radzinsky V.E. – concept and design of the study, approval of the final version of the article; Solovyeva A.V. – material collection and processing, text writing, editing; Kuleshov V.M., Katkova N.Yu., Mingaleva N.V., Korotkikh I.N., Oboskalova T.A., Vorontsova A.V. – material collection and processing. Conflicts of interest: The authors declare that there are no conflicts of interest. Funding: The investigation has not been sponsored. Patient Consent for Publication: The patients have signed an informed consent form to the publication of their data. Authors' Data Sharing Statement: The data supporting the conclusions of this investigation are available upon request from the corresponding author after approval by the principal investigator. For citation: Radzinsky V.E., Solovyeva A.V., Kuleshov V.M., Katkova N.Yu., Mingaleva N.V., Korotkikh I.N., Oboskalova T.A., Vorontsova A.V. A possibility for health improvement in overweight and obese women at the stage of pregravid preparation. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; 1: 83-90 (in Russian). https://dx.doi.org/10.18565/aig.2022.292

Keywords

pregravid preparation
obese and overweight women
anovulation
myo-inositol
D-chiroinositol

References

  1. Радзинский В.Е., Боташева Т.Л., Котайш Г.А., ред. Ожирение. Диабет. Беременность. Версии и контраверсии. Клинические практики. Перспективы. М.: ГЭОТАР-Медиа; 2020. 528с. [Radzinsky V.E., Botasheva T.L., Kotaysh G.A., ed. Obesity. Diabetes. Pregnancy. Versions and contraversions. Clinical practices. Perspectives. Moscow: GEOTAR-Media; 2020. 528 p. (in Russian)].
  2. ESHRE Early Pregnancy Guideline Development Group. Recurrent pregnancy loss. 2017. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx
  3. Gomes-Serrano M., Ponath V., Preuber C., von Strandmann E.P. Beyond the extracellular vesicles: technical hurdles, achieved goals and current challenges when working on adipose cells. Int. J. Mol. Sci. 2021; 22(7): 2262. https://dx.doi.org/10.3390/ijms22073362.
  4. Ferrazzi E., Sears B. Metabolic syndrom and complications of pregnancy. Springer; 2015. https://dx.doi.org/10.1007/978-3-319-16853-1.
  5. Aune D., Saugstad O.D., Henriksen T., Tonstad S. Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. JAMA. 2014; 311(15): 1538-46. https://dx.doi.org/10.1001/jama.2014.2269.
  6. Willis D., Mason H., Gilling Smith C., Franks S. Modulation by insulin of follicle stimulating hormone and luteinizing hormone action in human granulosa cells from normal and polycystic ovaries. J. Clin. Endocrinol. Metab. 1998; 81(1): 302-9. https://dx.doi.org/10.1210/jc.81.1.302.
  7. Hillier S.G. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum. Reprod. 1994; 99(2): 188-91. https://dx.doi.org/10.1093/oxfordjournals.humrep.a138480.
  8. Franks S., Robinson S., Willis D. Nutrition, insulin and polycistic ovary syndrome. Rev. Reprod. 1996; 1: 47-53. https://dx.doi.org/10.1530/ror.0.0010047.
  9. Чернуха Г.Е., Табеева Г.И., Удовиченко М.А. Неиспользованные возможности коррекции эндокринно-метаболических нарушений при синдроме поликистозных яичников. Акушерство и гинекология. 2019; 10: 140-7. https://dx.doi.org/10.18565/aig.2019.10.140-147. [Chernukha G.E., Tabeeva G.I., Udovichenko M.A. Unused opportunities for correction of endocrine and metabolic disorders in polycystic ovary syndrome. Obstetrics and Gynecology. 2019; (10): 140-7. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.10.140-147.
  10. Regidor P.-A., Schindler A.E., Lesoine B., Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm. Mol. Biol. Clin. Investig. 2018; 34(2): /j/hmbci.2018.34.issue-2/hmbci-2017-0067/hmbci-2017-0067.xml. https://dx.doi.org/10.1515/hmbci-2017-0067.
  11. International evidence-based guideline for the assestment and managment of policistic ovary syndrome. 2018. Available at: https://www.monash.edu/__data/assets/pdf_file/0004/1412644/PCOS_Evidence-Based-Guidelines_20181009.pdf
  12. Радзинский В.Е., Соловьева А.В., Кузнецова О.А., Смирнова Т.В. Прегравидарная подготовка: доказанная польза. Эссенциальные микронутриенты в составе поливитаминных комплексов. Доктор.Ру. 2020; 19(6): 30-5. https://dx.doi.org/10.31550/1727-2378-2020-19-6-30-35. [Radzinsky V.E., Soloviova A.V., Kuznetsova O.A., Smirnova T.V. Preconception Care: Proven Benefits. Essential Micronutrients as Part of Multivitamin Combinations. Doctor.Ru. 2020; 19(6): 30-5. (in Russian)]. https://dx.doi.org/10.31550/1727-2378-2020-19-6-30-35.
  13. Торшин И.Ю., Майорова Л.А., Уварова Е.В., Тапильская Н.И., Громова О.А. Хемореактомный анализ стереоизомеров инозитола: различные профили фармакологического действия миоинозитола и D-хироинозитола при нарушениях женской репродуктивной системы. Вопросы акушерства, гинекологии и перинатологии. 2020; 19(5): 57-69. https://dx.doi.org/10.20953/1726-1678-2020-5-57-69. [Torshin I.Yu., Mayorova L.A., Uvarova E.V., Tapilskaya N.I., Gromova O.A. Chemoreactomic analysis of inositol stereoisomers: different profiles of pharmacological activity of myo-inositol and D-chiro-inositol in females with reproductive system disorders. Gynecology, Obstetrics and Perinatology. 2020; 19(5): 57-69. (in Russian). https://dx.doi.org/10.20953/1726-1678-2020-5-57-69.
  14. Munro M.G., Critchley H.O.D., Fraser I.S.; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int. J. Gynecol. Obstet. 2018; 143(3): 393-408. https://dx.doi.org/10.1002/ijgo.12666.
  15. Радзинский В.Е., Соловьева А.В., Алейникова Е.Ю., Смирнова Т.В., Кузнецова О.А. Беременность и роды у женщин с железодефицитной анемией легкой степени, выявленной в I триместре. Акушерство и гинекология: новости, мнения, обучение. 2021; 9(3, Приложение): 6-13. https://dx.doi.org/10.33029/2303-9698-2021-9-3suppl-6-13. [Radzinsky V.E., Solovieva A.V., Aleinikova E.Yu., Smirnova T.V., Kuznetsova O.A. Pregnancy and childbirth in women with mild iron-deficiency anemia diagnosed in the first trimester. Obstetrics and Gynecology: News, Opinions, Training. 2021; 9(3) Supplement: 6-13. (in Russian)]. https://dx.doi.org/10.33029/2303-9698-2021-9-3suppl-6-13.
  16. Радзинский В.Е., ред. Анемии и репродуктивное здоровье. М.: Status Praesens; 2019. 200 с. [Radzinsky V.E., ed. Anemia and reproductive health. Moscow: Status Praesens; 2019. 200 p. (in Russian)].
  17. Vahratian A., Smith Y.R. Should access to fertility-related services be conditional on body mass index? Hum. Reprod. 2009; 24(7): 1532-7. http://dx.doi.org/10.1093/humrep/dep057.
  18. Franks S., Hardy K. What causes anovulation in polycystic ovary syndrome? Curr. Opin. Endocr. Metab. Res. 2020; 12: 59-65. https://dx.doi.org/10.1016/j.coemr.2020.03.001.
  19. Chavarro J.E., Rich-Edwards J.W., Rosner B.A., Willett W.C. Diet and lifestyle in the prevention of ovulatory disorder infertility. Obstet. Gynecol. 2007; 110(5): 1050-8. https://dx.doi.org/10.1097/01.AOG.0000287293.25465.e1.
  20. Rich-Edwards J.W., Spiegelman D., Garland M., Hertzmark E., Hunter D.J., Colditz G.A. et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology. 2002; 13(2): 184-90. https://dx.doi.org/10.1097/00001648-200203000-00013.
  21. Obirikorang C., Owiredu W.K.B.A., Adu-Afram S., Acheampong E., Asamoah E.A., Antwi-Boasiakoh E.K., Owiredu E. Assessing the variability and predictability of adipokines (adiponectin, leptin, resistin and their ratios) in non-obese and obese women with anovulatory polycystic ovary syndrome. BMC Res. Notes. 2019; 12(1): 513-21. https://dx.doi.org/10.1186/s13104-019-4546-z.
  22. Sylvia K.E., Lorenz T.K., Heiman J.R., Demas G.E. Physiological predictors of leptin vary during menses and ovulation in healthy women. Reprod. Biol. 2018; 18(1): 132-6. https://dx.doi.org/10.1016/j.repbio.2018.01.011.
  23. Ahrens K., Mumford S.L., Schliep K.C., Kissell K.A., Perkins N.J., Wactawski-Wende J., Schisterman E.F. Serum leptin levels and reproductive function during the menstrual cycle. Am. J. Obstet. Gynecol. 2014; 210(3): 248-e1. https://dx.doi.org/10.1016/j.ajog.2013.11.009.
  24. Boyd M., Ziegler J. Polycystic ovary syndrome, fertility, diet, and lifestyle modifications: a review of the current evidence. Top. Clin. Nutr. 2019; 34(1): 14-30. https://dx.doi.org/10.1097/TIN.0000000000000161.
  25. McGrice M., Porter J. The effect of low carbohydrate diets on fertility hormones and outcomes in overweight and obese women: a systematic review. Nutrients. 2017; 9(3): 204. https://dx.doi.org/10.3390/nu9030204.
  26. Azziz R., Carmina E., Chen Z., Dunaif A., Laven J.S., Legro R.S. et al. Polycystic ovary syndrome. Nat. Rev. Dis. Prim. 2016; 2: 16057. https://dx.doi.org/10.1038/nrdp.2016.57.
  27. Barbe A., Bongrani A., Mellouk N., Estienne A., Kurowska P., Grandhaye J. et al. Mechanisms of adiponectin action in fertility: an overview from gametogenesis to gestation in humans and animal models in normal and pathological conditions. Int. J. Mol. Sci. 2019; 20(7): 1526. https://dx.doi.org/10.3390/ijms20071526.
  28. Teede H., Misso M., Tassone E.C., Dewailly D., Ng E.H., Azziz R. et al. Anti-mullerian hormone in PCOS: A review informing international guidelines. Trends Endocrinol. Metabol. 2019; 30(7): 467-78. https://dx.doi.org/10.1016/j.tem.2019.04.006.
  29. Majunder A.L., Biswas B.B., eds. Biology of inositols and phosphoinositides. Series: Subcellular biochemistry. Springer; 2006 January; vol.39. https://dx.doi.org/10.1007/0-387-27600-9.
  30. Milewska E.M., Czyzyk A., Meczekalski B., Genazzani A.D. Inositol and human reproduction. From cellular metabolism to clinical use. Gynecol. Endocrinol. 2016; 32(9): 690-5. https://dx.doi.org/10.1080/09513590.2016.1188282.
  31. Ravanos K., Monastra G., Pavlidou T., Goudakou M., Prapas N. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur. Rev. Med. Pharmacol. Sci. 2017; 21(23): 5491-8. https://dx.doi.org/10.26355/eurrev_201712_13940.
  32. Özay Ö.E., Özay A.C., Çağlıyan E., Okyay R.E., Gülekli B. Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: A prospective, controlled, randomized trial. Gynecol. Endocrinol. 2017; 33(7): 524-8. https://dx.doi.org/10.1080/09513590.2017.1296127.
  33. Sacchi S., Marinaro F., Tondelli D., Lui J., Xella S., Marsella T. et al. Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol. Reprod. Biol. Endocrinol. 2016; 14(1): 52. https://dx.doi.org/10.1186/s12958-016-0189-2.

Received 08.12.2022

Accepted 24.01.2023

About the Authors

Viktor Е. Radzinsky, Corresponding Member of the RAS, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology with the Course of Perinatology, Medical Institute of Peoples’ Friendship University of Russia (RUDN University), radzinsky@mail.ru, https://orcid.org/0000-0003-4956-0466,
117198, Russia, Moscow, Miklukho-Maklaya str., 6.
Alina V. Solovyeva, Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology with the Course of Perinatology, Medical Institute of Peoples’ Friendship University of Russia (RUDN University), av_soloveva@mail.ru, https://orcid.org/0000-0001-6711-1563, 117198, Russia, Moscow, Miklukho-Maklaya str., 8.
Vitaliy M. Kuleshov, Dr. Med. Sci., Professor, Professor at the Obstetrics and Gynecology Department, Novosibirsk State Medical University, Ministry of Health of Russia, kuleshov_vm@mail.ru, 630091, Russia, Novosibirsk, Krasny prospect, 52.
Nadezhda Yu. Katkova, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Additional Vocational Education, Privolzhsky Research Medical University, Ministry of Health of Russia, katkova_nu@inbox.ru, SPIN-код: 7967-5759, Author ID: 340045, 603005, Russia, Nizhny Novgorod,
Minin and Pozharsky sqr., 10/1.
Natalya V. Mingaleva, Dr. Med. Sci., Chief Freelance Specialist in Outpatient Obstetric and Gynecological Care of the Ministry of Health of the Krasnodar Territory; Professor, Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University, Ministry of Health of Russia, mingalevaN008@yandex.ru,
https://orcid.org/0000-0001-5440-3145, 350063, Russia, Krasnodar, M. Sedin str., 4.
Irina N. Korotkikh, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medicine, N.N. Burdenko Voronezh State Medical University, Ministry of Health of Russia, korotkikh_1950@mail.ru, 394066, Russia, Voronezh, Moskovsky Ave., 151.
Tatyana A. Oboskalova, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, Ural State Medical University, Ministry of Health of Russia, oboskalova.tat@yandex.ru, https://orcid.org/0000-0003-0711-7896, SPIN: 9364-2321, 620219, Russia, Ekaterinburg, Repin str., 3.
Anna V. Vorontsova, PhD, Associate Professor, Department of Obstetrics and Gynecology, Ural State Medical University, Ministry of Health of Russia,
a_valerevna@mail.ru, https://orcid.org/0000-0002-0509-3328620219, 620219, Russia, Ekaterinburg, Repin str., 3.

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.